Enzyme Replacement Therapy Market Drivers and Forecasts by 2028

The enzyme replacement therapy market is expected to grow from US$ 9,673.39 million in 2021 to US$ 15,184.70 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

Enzyme replacement therapy (ERT) is performed to treat congenital enzyme deficiencies by using enzyme or protein having enzymatic activity. Animal, human, and recombinant engineered enzymes are a few sources of enzyme required for treatment. The therapy is generally applied in rare and lysosomal storage diseases, including Pompe disease, Fabry disease, Gaucher disease, Tay-Sachs disease, and Hurler syndrome. The most common ERT method is IV infusions, in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids. The growth of the global enzyme replacement therapy market  is attributed to the rising prevalence of lysosomal storage diseases (LSDs) and rapid regulatory approval with other marketing benefits for drug with orphan drug designation. However, the cutthroat competition among market players hinders the market growth.

The report offers insights and in-depth analysis of the global enzyme replacement therapy market, emphasizing various parameters including market trends, technological advancements, market dynamics, and competitive landscape analysis of global leading market players. It also includes the impact of the COVID-19 pandemic on the market across all regions. Due to the COVID-19 pandemic, many health authorities focused on pandemic-related care. Moreover, many patients requiring enzyme replacement therapy missed their infusions in March 2020 due to the inadequacy of hospital services dealing with the burden of COVID-19 patients. Patients requiring ERT claimed to feel anxious during hospital admissions or regarding drug supply. Also, studies revealed that some patients had depression and an increased amount of anxiety. Thus, scheduled enzyme replacement therapy (ERT) sessions were disrupted during COVID-19 pandemic leading to a negative impact on the market.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Enzyme Replacement Therapy Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Geography-Based Insights

By geography, the global enzyme replacement therapy market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of the MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Market Insights

Rising Prevalence of Lysosomal Storage Diseases (LSDs)

A lysosome is a membrane-bound cell organelle that contains digestive enzymes. A lysosome is the key cellular hub for macromolecule catabolism, recycling, and signaling. Any defect in these functions leads to the accumulation or storage of macromolecules in lysosomes, resulting in cellular damage. The leading cause of lysosomal storage diseases (LSDs) is mutations in the genes responsible for encoding a lysosomal enzyme. Additionally, LSDs are characterized as an inborn metabolism error that results in an enzyme's absence or deficiency. Infants and children suffer more severely compared to adults as children can inherit the defective gene from one or both parents. However, since the last decade, the pattern has been changing, and LSDs are more common in adults

Moreover, LSDs are approximately 70 diseases, including Gaucher disease, Niemann-Pick disease, Fabry disease, Tay-Sachs disease, Mucopolysaccharidoses (MPS) diseases, and Pompe disease. These disorders are individually rare, but collectively they are significantly prevalent and affect 1 in 5,000 live births. Many countries conducted surveys to understand the prevalence pattern, and the overall prevalence was rising. For instance, a study published in The Lancet Regional Health entitled "Prevalence of lysosomal storage disorders in Australia from 2009 to 2020". The study revealed the following outcomes:

• The prevalence in the Australian population is 1.6 times (1 per 4,800 live births), higher than the reported prevalence in 1996 (1 per 7,700 live births).
• Fabry disease was most prevalent, representing 34% of all diagnoses (up to 2020).
• LSDs are more common in adulthood than in childhood

Thus, the rising prevalence of LSDs and limited therapies to cure the disease are driving the growth of the global enzyme replacement therapy market

Enzyme Type-Based Insights

Based on enzyme type, the global enzyme replacement therapy market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. In 2021, the other enzymes segment accounted for the largest market share. The same segment is expected to register the highest CAGR in the market from 2022 to 2028.

Therapeutic Conditions-Based Insights

Based on therapeutic conditions, the global enzyme replacement therapy market is segmented into Gaucher's disease, Fabry's Disease, Pompe's Disease, SCID, MPS, and other therapeutic conditions. The Gaucher’s disease segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.

Route of Administration-Based Insights

Based on route of administration, the global enzyme replacement therapy market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2021 and is anticipated to register a higher CAGR during the forecast period.

Enzyme Replacement Therapy Market Regional Insights

The regional trends and factors influencing the Enzyme Replacement Therapy Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Enzyme Replacement Therapy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Enzyme Replacement Therapy Market Report Scope

Enzyme Replacement Therapy Market Players Density: Understanding Its Impact on Business Dynamics

The Enzyme Replacement Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

End User-Based Insights

Based on end user, the global enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2021. However, the infusion centers segment is expected to register the highest CAGR during the forecast period.

The global enzyme replacement therapy market players adopt organic strategies, including product launch and expansion, to expand their footprint and product portfolio worldwide and meet the growing demand. A few major players contributing to the market are Takeda Pharmaceutical Company Limited; Sanofi S.A.; AbbVie Inc.; BioMarin Pharmaceutical Inc.; Amicus Therapeutics; Alexion Pharmaceuticals, Inc. (AstraZeneca); Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Recordati S.p.A.; Pfizer Inc.; and CHIESI Farmaceutici S.p.A.